Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

• Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma

  2026 Cell Reports Medicine article Medicine Lymphoma Diagnosis and Treatment Open access

  0

  citations
• Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

  2025 Blood Advances article Medicine Lymphoma Diagnosis and Treatment Open access

  6

  citations
• Improving CD3 bispecific antibody therapy in solid tumors using combination strategies

  2025 Frontiers in Oncology article Medicine Monoclonal and Polyclonal Antibodies Research Open access

  5

  citations
• Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy

  2025 Journal for ImmunoTherapy of Cancer article Immunology and Microbiology Immunotherapy and Immune Responses Open access

  4

  citations
• Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial

  2024 Blood Neoplasia article Medicine Lymphoma Diagnosis and Treatment Open access

  5

  citations
• Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

  2023 Blood article Medicine CAR-T cell therapy research Open access cited by 1 patent

  355

  citations

6 results

• Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

  2020 The Lancet Haematology article Medicine Lymphoma Diagnosis and Treatment Open access cited by 2 patents

  345

  citations

1 result